Furosemide

Furosemide, sold as Lasix, is a diuretic that works on the kidney, taken by mouth in the form read here. The US label read, for Lasix tablets, lists swelling from fluid build-up in people with congestive heart failure, cirrhosis of the liver and kidney disease including the nephrotic syndrome, in adults and children. It says the oral form may also be used in adults for high blood pressure, alone or with other blood pressure medicines.

Also called Lasix

  • Drug
  • In this atlas

Overview

Technical summary

RxNorm ingredient 4603; UNII 7LXU5N7ZO5. MeSH descriptor D005665 is Furosemide. Class: Loop Diuretic (FDA established pharmacologic class, RxClass). The label read is the Validus Pharmaceuticals LLC label for Lasix tablets, application NDA016273, effective 2025-09-30 in openFDA; the cluster that wrote the loop diuretic class page read the same label. Other furosemide products in openFDA, including the injection labels and the Lasix ONYU subcutaneous product, were not read. This page records label indications, the mechanism sentence and the class only: no trial result and no dose is given.

About this drug

Level
Substance
Mechanism
The label says furosemide mainly inhibits the absorption of sodium and chloride in the kidney, including in the loop of Henle.

Claims and evidence

Context Adults and pediatric patients with edema, and adults with hypertension, as described in the US label of a loop diuretic

Recipient
Mixed recipients
Population
Patients described in the indications section of the label: adults and pediatric patients with edema associated with congestive heart failure, cirrhosis of the liver or renal disease, and adults with hypertension.
Care setting
Prescription medicine, as described in the US label
Geography
United States (US drug label)
Life stage
Adults and pediatric patients for edema; adults for hypertension, as the label states
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (label statement)
Eligibility: 2 inclusion criteria; exclusion criteria not stated
Included
  • Adults and pediatric patients with edema associated with congestive heart failure, cirrhosis of the liver or renal disease
  • Adults with hypertension
Excluded
None stated
  • Description Evidence stage not applicable Certainty not assessed

    The US label of Lasix (furosemide tablets, Validus Pharmaceuticals LLC, application NDA016273; the version dated 2025-09-30 in openFDA) lists the treatment of edema associated with congestive heart failure, cirrhosis of the liver and renal disease, including the nephrotic syndrome, in adults and pediatric patients. It says oral Lasix may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents.

    Applies to Mixed recipients Adults and pediatric patients with edema, and adults with hypertension, as described in the US label of a loop diuretic

    Certainty method
    Not assessed
    Limitations
    This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Other furosemide labels, including injections, list different routes and uses. Contraindications, warnings, interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-18
    Next evidence check due
    Not scheduled
    Sources and citations (3)
    1. Supports openFDA drug label record for LASIX (furosemide tablets), Validus Pharmaceuticals LLC label: indications and class description

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 2c9b4d8f-0770-482d-a9e6-9c616a440b1a (manufacturer Validus Pharmaceuticals LLC, application NDA016273), returned on 2026-11-09. The label text is dated 2025-09-30 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].indications_and_usage[0], INDICATIONS AND USAGE, Edema
      How it applies
      Label passage quoted in the research quote table (LB-04, LB-05).
      Retrieved
      Source effective date
      2025-09-30
      Source state
      Current
      Version fingerprint
      ed9855aad2ab51bda46903f2319af7d32d4fcf9954b059cd6afc33672d16a4f0
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Supports openFDA drug label record for LASIX (furosemide tablets), Validus Pharmaceuticals LLC label: indications and class description

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 2c9b4d8f-0770-482d-a9e6-9c616a440b1a (manufacturer Validus Pharmaceuticals LLC, application NDA016273), returned on 2026-11-09. The label text is dated 2025-09-30 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].indications_and_usage[0], INDICATIONS AND USAGE, Hypertension
      How it applies
      Label passage quoted in the research quote table (LB-06).
      Retrieved
      Source effective date
      2025-09-30
      Source state
      Current
      Version fingerprint
      ed9855aad2ab51bda46903f2319af7d32d4fcf9954b059cd6afc33672d16a4f0
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    3. Background openFDA drug label record for LASIX (furosemide tablets), Validus Pharmaceuticals LLC label: indications and class description

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 2c9b4d8f-0770-482d-a9e6-9c616a440b1a (manufacturer Validus Pharmaceuticals LLC, application NDA016273), returned on 2026-11-09. The label text is dated 2025-09-30 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20250930.
      Retrieved
      Source effective date
      2025-09-30
      Source state
      Current
      Version fingerprint
      ed9855aad2ab51bda46903f2319af7d32d4fcf9954b059cd6afc33672d16a4f0
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.

Clinical links

Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.

Record details

Record id
cardio:furosemide
Content hash
7f147c8cd6a0a72821f9a0bca0d97fbc555914baa702999a9da85a39351ab4cf